InspireMD, Inc. (NSPR)
| Market Cap | $36.14M-65.9% |
| Revenue (ttm) | $10.56M |
| Net Income | -$49.54M |
| EPS | -$0.57 |
| Shares Out | 54.13M |
| PE Ratio | n/a |
| Forward PE | -1.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 268,796 |
| Open | $0.65 |
| Previous Close | $0.65 |
| Day's Range | $0.62 - $0.69 |
| 52-Week Range | $0.43 - $2.17 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $2.67(+299.38%) |
| Earnings Date | Nov 12, 2026 |
About NSPR
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.
InspireMD, Inc. Stock Analysis — InsiderScore
InspireMD, Inc. scored higher than 46% of companies evaluated by InsiderBuying, and ranked 28th out of 50 stocks in the healthcare sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at InspireMD, Inc. bought $455.0K of stock across 5 purchases in the last 90 days, the largest of them $200.0K.
The average purchase added about 26% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$NSPR stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in NSPR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NSPR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NSPR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NSPR Revenue by Segment or Geography
| Selling and marketing (S&M) | $2.39M | 20.54% |
| Material and Labor | $1.73M | 14.80% |
| Other G&A | $1.47M | 12.58% |
| Clinical trials | $1.22M | 10.50% |
| Payroll and Benefits | $1.19M | 10.17% |
| Inventory write-off | $1.08M | 9.31% |
| Other R&D | $1.07M | 9.23% |
| Restructuring and other | $1.07M | 9.22% |
| Other S&M | $425.00K | 3.65% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New NSPR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NSPR from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from NSPR’s recent data — informational, not investment advice
